Global health challenges

Neglected tropical diseases

Neglected Tropical Diseases

Adding to their +100 R&D projects for NTDs, our members are also involved in over 40 partnerships to support capacity-strengthening in developing economies, and continue to deliver on their 2012 pledge of 1.4 billion annual treatments in donations.

Stopping neglected diseases is achievable. Success relies on a multi-stakeholder approach to not only drive further research but also integrate environmental improvements, boost capacity-strengthening efforts, improve health policies, provide better screening and broaden availability of quality, safe and effective medicines.

Our industry is currently working on +100 R&D projects to develop new or improved medicines and vaccines for 11 neglected tropical diseases that each year kill or disable millions of people in low- and middle-income countries. Nearing the end of what is on average a 10-15 year R&D process, IFPMA member companies and their partners are approaching imminent NTDs breakthroughs, with late stage testing (Phase III) of treatments and vaccines of 7 compounds, within the disease areas of American Trypanosomiasis (Chagas disease), dengue, Human African trypanosomiasis (sleeping sickness), lymphatic filariasis, rabies, and trachoma. Most of the R&D projects for neglected tropical diseases are collaborative efforts, involving partnerships between IFPMA member companies and more than 50 partners from universities, public and private sector institutes and non-governmental organizations.

The latest G-FINDER 2016 finds that “Industry investment in neglected disease R&D in 2015 was the highest ever recorded in the G-FINDER survey”. The pharmaceutical industry contributed USD471 million to global R&D efforts, and is the only sector (compared to public and philanthropic sectors) to have recorded year-on-year growth for the last four years.

Solving major global health issues like NTDs requires concerted action and commitment from a broad range of partners. As one the WHO’s “community of partners” fighting NTDs, our industry is committed to help end this suffering by bringing its unique expertise in pharmaceutical innovation to the fight against NTDs. For decades individual pharmaceutical companies have researched, developed, and donated medicines to fight disease and improve patients’ lives. In January 2012 the research-based pharmaceutical industry jointly pledges a further 14 billion treatments to help end these debilitating diseases (London Declaration). Our industry continues to deliver on its pledge of 1.4 billion annual treatments through 2020 to control or eliminate the ten neglected tropical diseases responsible for more than 90% of the global neglected diseases burden. In 2015 alone, pharmaceutical companies donated an estimated 2.4 billion tablets, enough for 1.5 billion treatments to prevent and treat NTDs.

Finally, IFPMA member companies are also involved in over 40 partnerships to support capacity-strengthening the projects that aim to bolster local health systems and capacity, as well as provide safe water and sanitation, and public awareness on disease prevention.

The TDR Clinical Research and Development Fellows (CDF) program, which began in 1999 with the support of IFPMA, gives postgraduate fellows from hospitals, academic and research institutions the opportunity to spend 12 months working in the clinical department of a host pharmaceutical company, product development partnership or research institution.

The pharmaceutical industry

contributed USD 471 million to global R&D efforts in 2015

14 billion treatments

donated this decade to support the elimination or control of 10 key neglected tropical diseases

40 health partnerships programs

combine prevention, training and treatment

Related Resources




This website uses cookies to ensure you get the best experience on our website. Learn More